8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 1, 2010

AMAG PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-14732	04-2742593
(Commission File Number)	(IRS Employer Identification No.)
100 Hayden Avenue
Lexington, Massachusetts	02421
(Address of principal executive offices)	(Zip Code)

(617) 498-3300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

The following information and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

On March 1, 2010, AMAG Pharmaceuticals, Inc., or the Company, issued a press release regarding its operating results and revenues for the quarter and year ended December 31, 2009 and its intention to hold a conference call regarding such financial results, business highlights, commercial plans and development programs. A copy of the Company’s press release is furnished herewith as Exhibit 99.1.

Item 9.01.  Financial Statements and Exhibits.

(d)  Exhibits.

The Company hereby furnishes the following exhibit:

99.1 Press Release dated March 1, 2010.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMAG PHARMACEUTICALS, INC.
By:	/s/ Joseph L. Farmer
	Joseph L. Farmer
	General Counsel and Senior Vice
	President of Legal Affairs
Date: March 1, 2010

3

EXHIBIT INDEX

Exhibit  Number	Description
99.1	Press Release dated March 1, 2010.

4

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

AMAG Pharmaceuticals Announces Fourth Quarter and Year End 2009 Financial Results

LEXINGTON, MA (March 1, 2010) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.

Business Highlights

·AMAG reported fourth quarter 2009 Feraheme® net product revenues of $12.8 million, including $1.3 million of the $11.5 million in previously deferred product revenues.

·To date, more than 1,300 providers have purchased Feraheme®(ferumoxytol) Injection; collectively, these providers purchased approximately 240,000 grams of all forms of IV iron over the past 52 weeks(1).

·Of the providers that have purchased Feraheme to date, more than 1,100 are treating non-dialysis dependent chronic kidney disease patients and more than 60 percent have purchased on a repeat basis.

·AMAG estimates that more than half of Feraheme provider demand in 2009 was outside of the dialysis setting.

“We are very pleased with the progress made by AMAG in 2009,” said Brian J.G. Pereira, MD, President and Chief Executive Officer of AMAG Pharmaceuticals, Inc.  “In addition to receiving marketing approval for our first therapeutic product in the U.S., we launched Feraheme within two weeks of approval, and ended the year with a strong foundation from which to grow.”

Dr. Pereira continued, “We enter 2010 with ambitious plans to continue the successful launch of Feraheme for the treatment of iron deficiency anemia in adult chronic kidney disease patients in the U.S.; expand the development of Feraheme to IDA patients, with and without CKD around the world; advance our ferumoxytol imaging program; and secure a commercial partner for Feraheme in the E.U.”

1

As of December 31, 2009, the Company’s cash, cash equivalents, investments and settlement rights associated with certain auction rate securities totaled $129.5 million. In January 2010, AMAG successfully completed a follow-on offering of 3.6 million shares of common stock, with net proceeds to the Company of approximately $165.6 million. Revenues for the quarter ended December 31, 2009 were $13.1 million as compared to revenues of $0.6 million for the same period in 2008.  Revenues for the year ended December 31, 2009 were $17.2 million as compared to $1.9 million for the same period in 2008. The increases in revenues in 2009 over the comparable 2008 periods were attributable to Feraheme product sales following its approval and subsequent launch in July 2009.

Total operating costs and expenses for the quarter ended December 31, 2009 were $33.3 million as compared to $23.8 million for the same period in 2008.  Total operating costs and expenses for the year ended December 31, 2009 were $115.1 million as compared to $81.5 million for the same period in 2008. The increases in operating costs and expenses in 2009 over the comparable 2008 periods were primarily due to increased selling, general and administrative expenses associated with the commercialization of Feraheme.

The Company reported a net loss of $18.4 million, or a loss of $1.07 per basic and diluted share, for the quarter ended December 31, 2009, as compared to a net loss of $21.8 million, or a loss of $1.28 per basic and diluted share, for the same period in 2008.  Net loss for the year ended December 31, 2009 was $93.4 million, or a loss of $5.46 per basic and diluted share, as compared to a net loss of $71.6 million, or a loss of $4.22 per basic and diluted share for the same period in 2008.

Conference Call and Webcast Access

AMAG Pharmaceuticals, Inc. will host a webcast with slides and conference call today at 8:00 a.m. ET to discuss the Company’s financial results, business highlights, commercial plans and development programs.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access.  A telephone replay will be available from approximately 11:00 a.m. ET on March 1, 2010 through midnight March 3, 2010.  To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access.  The passcode for the live call and the replay is 54914959.

The call will be webcast with slides and accessible through the Investors section of the Company’s website at www.amagpharma.com.  The webcast replay will be available from approximately 11:00 a.m. ET on March 1, 2010 through midnight April 1, 2010.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia

2

and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.  On June 30, 2009, AMAG received approval from the U.S. Food and Drug Administration to market Feraheme® (ferumoxytol) Injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.  For additional company and product information, please visit www.amagpharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding our plans to continue the successful launch of Feraheme for the treatment of iron deficiency anemia in chronic kidney disease patients in the U.S.; expand the development of Feraheme to IDA patients, with and without CKD around the world; advance our ferumoxytol imaging program; and secure a commercial partner for Feraheme in the E.U. are forward looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward looking statements. Such risks and uncertainties include: (1) uncertainties regarding our ability to successfully compete in the intravenous iron replacement market, (2) the fact that we have limited experience developing and commercializing a pharmaceutical product on our own, particularly outside of the U.S., (3) uncertainties regarding our ability to ensure favorable coverage, pricing and reimbursement for Feraheme, (4) uncertainties regarding our ability to manufacture Feraheme, (5) uncertainties relating to our patents and proprietary rights, and (6) other risks identified in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2009. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Important Safety Information about Feraheme

Feraheme is contraindicated in patients with evidence of iron overload, known hypersensitivity to Feraheme or any of its components, and patients with anemia not caused by iron deficiency.

In clinical studies, hypotension was reported in 1.9% (33/1,726) of subjects receiving Feraheme, including three patients with serious hypotensive reactions.  Serious hypersensitivity reactions were reported in 0.2% (3/1726) of patients. Patients should be observed for signs and symptoms of hypersensitivity for at least 30 minutes following Feraheme injection and the drug should only be administered when treatment for hypersensitivity reactions is readily available.  Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy.  As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging but will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging.   In clinical trials, the most commonly occurring adverse reactions in Feraheme treated patients versus oral iron treated patients were diarrhea, nausea, dizziness, hypotension, constipation and peripheral edema.

3

AMAG Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(unaudited, amounts in thousands, except for per share data)

	Three Months Ended December 31,						Twelve Months Ended December 31,
	2009			2008			2009			2008
Revenues:	$	13,146		$	580		$	17,178		$	1,938
Operating costs and expenses (1):
Cost of product sales	824			214			1,013			292
Research and development expenses	8,978			9,563			36,273			31,716
Selling, general and administrative expenses	23,460			13,997			77,829			49,536
Total operating costs and expenses	33,262			23,774			115,115			81,544
Operating Loss	(20,116		)	(23,194		)	(97,937		)	(79,606		)
Interest and dividend income, net	612			1,653			3,154			9,139
Other income (expense)	3			(221		)	164			(1,458		)
Net loss before income taxes	(19,501		)	(21,762		)	(94,619		)	(71,925		)
Income tax benefit	1,089			—			1,268			278
Net loss	$	(18,412	)	$	(21,762	)	$	(93,351	)	$	(71,647	)
Net loss per share - basic and diluted:	$	(1.07	)	$	(1.28	)	$	(5.46	)	$	(4.22	)
Weighted average shares outstanding used to compute net loss per share:
Basic and diluted	17,258			17,007			17,109			16,993

(1) Stock-based compensation included in operating costs and expenses:
Cost of product sales	$	43	$	—		$	43	$	—
Research and development	948		1,119			4,446		3,760
Selling, general and administrative	2,798		(2,845		)	10,932		4,277

4

AMAG Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited, amounts in thousands)

	December 31, 2009		December 31, 2008
Cash and cash equivalents	$	50,126	$	64,182
Short-term investments and settlement rights	30,366		94,914
Accounts receivable, net	27,350		408
Inventories	9,415		96
Other current assets	5,472		4,710
Total current assets	122,729		164,310
Net property, plant & equipment	12,417		11,223
Long-term investments and settlement rights	49,013		55,901
Other assets	460		521
Total assets	$	184,619	$	231,955
Accounts payable	$	5,432	$	2,305
Accrued expenses	21,931		11,571
Deferred revenues	10,198		516
Total current liabilities	37,561		14,392
Long-term liabilities	4,081		4,149
Total stockholders’ equity	142,977		213,414
Total liabilities and stockholders’ equity	$	184,619	$	231,955

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

(1)IMS Health DDD derived annual grams for the period ending February 12, 2010.

AMAG Pharmaceuticals, Inc. Contacts
Amy Sullivan, 617-498-3303
Carol Miceli, 617-498-3361

# # #

5